ANI Pharmaceuticals ANIP Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from ANI Pharmaceuticals’s reported figures.
Based on trailing twelve months.
The official record: ANI Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about ANI Pharmaceuticals's return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ANI Pharmaceuticals's return on equity?
- ANI Pharmaceuticals (ANIP) reported return on equity of 18.8% in Q1 2026.
- How has ANI Pharmaceuticals's return on equity changed year-over-year?
- ANI Pharmaceuticals's return on equity increased by 488.6% year-over-year, from -4.8% to 18.8%.
- What is the long-term trend for ANI Pharmaceuticals's return on equity?
- Over 5 years (2020 to 2025), ANI Pharmaceuticals's return on equity has grown at a 8.5% compound annual growth rate (CAGR), from -11% to 16.6%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.